CytoMed Therapeutics Ltd
GDTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.53M
Close$
$-1.25
241.7% downside
Current Fair Value
241.7% downsideOvervalued by 241.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.53 Million |
|---|---|
| Enterprise Value | $9.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.33 |
| Beta | 0.05 |
| Outstanding Shares | 11,880,430 |
Return
| Return on Equity | -97.38% |
|---|---|
| Return on Assets | -69.03% |
| Return on Invested Capital | -95.79% |
Valuation & Multiples
| P/E Ratio | -2.48 |
|---|---|
| PEG | -2.45 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 19.5 |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$126,857
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data